ArticleDiscover oncology2026
A multicenter study identifies an immune inflammatory and nutritional prognostic signature in intrahepatic cholangiocarcinoma.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundImmune dysfunction, systemic inflammation, and malnutrition are closely associated with tumor progression and prognosis in intrahepatic cholangiocarcinoma (ICC). This multicenter retrospective study aimed to evaluate the prognostic value of immune-inflammatory-nutritional biomarkers and to establish a novel cholangiocarcinoma immune-inflammatory-nutritional score (CIINS).
methodsA total of 284 ICC patients who underwent curative surgical resection at three medical centers were retrospectively analyzed and divided into a training cohort (n = 182) and a validation cohort (n = 102). Twelve immune, inflammatory, and nutritional biomarkers derived from routine preoperative blood tests were assessed. The CIINS was constructed using least absolute shrinkage and selection operator Cox regression. Nomograms integrating CIINS with independent clinicopathological factors were developed to predict overall survival (OS) and progression-free survival (PFS). Model performance was evaluated using time-dependent receiver operating characteristic curves, calibration plots, and decision curve analysis.
resultsThe CIINS consisted of four biomarkers: neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, neutrophil-to-albumin ratio, and prognostic nutritional index. Patients were stratified into high- and low-CIINS groups using the median value. High CIINS was significantly associated with poorer OS and PFS in both the training (both p < 0.001) and validation cohorts (OS: p = 0.006; PFS: p = 0.007). Elevated CIINS correlated with obstructive jaundice, increased CA19-9 levels, and advanced AJCC TNM stage. Multivariate analysis confirmed CIINS as an independent prognostic factor. CIINS-based nomograms demonstrated good discrimination and calibration for survival prediction.
conclusionCIINS is a simple and clinically applicable prognostic tool for patients with resected ICC, supporting individualized risk stratification and postoperative management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.